Keyword: biopharmaceuticals
News
18.12.2015
- US biopharmaceutical group Amgen is buying back from GlaxoSmithKline (GSK) all of its remaining rights to the bone drugs Prolia (denosumab), Xgeva (denosumab) and Vectibix...
News
02.12.2015
- US biopharmaceutical company Baxalta has received European marketing approval for its hemophilia treatment Obizur. The drug is said to be the first recombinant porcine sequence...
Strategy & Management
07.10.2015
- The ability to rapidly deploy manufacturing capacity will be a strategic asset of the pharmaceutical industry in the future. NNE Pharmaplan has developed the “Bio on demand”...
Plant Construction & Process Technology
07.10.2015
- The need to get products quicker to market, to ensure greater regulatory compliance and to boost efficiencies while reducing operational cost is a challenging goal. Owing to the...
Plant Construction & Process Technology
07.10.2015
- With biosimilars the pharmaceutical industry and health-care business move into a relatively young discipline with high sales potential. The follow-up drugs of biopharmaceuticals...
News
21.09.2015
- US biopharmaceutical group Amgen is to acquire Dezima Pharma, a privately held Dutch biotechnology company focused on developing treatments for dyslipidemia. The transaction is...
News
03.09.2015
- Swiss drugmaker Novartis has announced it will cooperate with US biopharmaceutical group Amgen to develop and sell neuroscience treatments for conditions such as Alzheimer's...
News
21.08.2015
- US biotechnology company United Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Boucher (PPRV) to a subsidiary of biopharmaceutical firm AbbVie for $350...
